Atalanta Sosnoff Capital LLC Sells 2,896 Shares of Eli Lilly and Company (NYSE:LLY)

Atalanta Sosnoff Capital LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 135,791 shares of the company's stock after selling 2,896 shares during the quarter. Eli Lilly and Company makes up approximately 2.3% of Atalanta Sosnoff Capital LLC's portfolio, making the stock its 10th biggest position. Atalanta Sosnoff Capital LLC's holdings in Eli Lilly and Company were worth $104,830,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Garner Asset Management Corp grew its position in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after purchasing an additional 12 shares in the last quarter. FWG Holdings LLC raised its stake in Eli Lilly and Company by 0.6% during the 4th quarter. FWG Holdings LLC now owns 2,023 shares of the company's stock valued at $1,640,000 after purchasing an additional 12 shares during the last quarter. Morling Financial Advisors LLC increased its holdings in Eli Lilly and Company by 4.7% in the 4th quarter. Morling Financial Advisors LLC now owns 266 shares of the company's stock valued at $205,000 after buying an additional 12 shares during the period. Prestige Wealth Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 2.0% during the fourth quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company's stock valued at $468,000 after acquiring an additional 12 shares during the period. Finally, Applied Finance Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 1.4% in the fourth quarter. Applied Finance Capital Management LLC now owns 855 shares of the company's stock valued at $660,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,002.80.

Eli Lilly and Company Stock Up 3.9 %

Shares of LLY stock traded up $31.00 during trading on Friday, reaching $825.10. The company's stock had a trading volume of 6,056,616 shares, compared to its average volume of 3,477,597. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock's 50-day moving average price is $825.36 and its 200 day moving average price is $814.96. The company has a market capitalization of $782.34 billion, a price-to-earnings ratio of 70.46, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the business posted $2.58 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.